DE602006014535D1 - Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen - Google Patents

Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen

Info

Publication number
DE602006014535D1
DE602006014535D1 DE602006014535T DE602006014535T DE602006014535D1 DE 602006014535 D1 DE602006014535 D1 DE 602006014535D1 DE 602006014535 T DE602006014535 T DE 602006014535T DE 602006014535 T DE602006014535 T DE 602006014535T DE 602006014535 D1 DE602006014535 D1 DE 602006014535D1
Authority
DE
Germany
Prior art keywords
proanp
probnp
level
cardiac
increased level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006014535T
Other languages
English (en)
Inventor
Georg Hess
Andrea Horsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of DE602006014535D1 publication Critical patent/DE602006014535D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE602006014535T 2005-06-07 2006-06-07 Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen Active DE602006014535D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05012196A EP1731910A1 (de) 2005-06-07 2005-06-07 Gebrauch von NT-proANP und NT-proBNP für die Diagnose von Herzkrankheiten
PCT/EP2006/062957 WO2006131529A1 (en) 2005-06-07 2006-06-07 Use of nt-proanp and nt-probnp for diagnosing cardiac diseases

Publications (1)

Publication Number Publication Date
DE602006014535D1 true DE602006014535D1 (de) 2010-07-08

Family

ID=34937270

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006014535T Active DE602006014535D1 (de) 2005-06-07 2006-06-07 Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen

Country Status (8)

Country Link
US (1) US7608418B2 (de)
EP (2) EP1731910A1 (de)
JP (1) JP4828600B2 (de)
CN (1) CN101194167A (de)
AT (1) ATE469353T1 (de)
CA (1) CA2607264A1 (de)
DE (1) DE602006014535D1 (de)
WO (1) WO2006131529A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
CN102533972B (zh) 2002-05-09 2014-07-02 布赖汉姆妇女医院 作为心血管病的标志和治疗靶的1l1rl-1
ES2344993T3 (es) * 2006-03-24 2010-09-13 F. Hoffmann-La Roche Ag Medios y metodos para la diferenciacion de la necrosis de miocardio aguda y cronica en pacientes sintomaticos.
CA2650201C (en) 2006-04-24 2020-10-20 James V. Snider Predicting mortality and detecting severe disease
EP3059594A1 (de) 2006-05-01 2016-08-24 Critical Care Diagnostics, Inc. Prognose von herz-kreislauf-erkrankung
WO2008030122A1 (en) 2006-09-07 2008-03-13 University Of Otago Biomarkers
EP2498095A3 (de) * 2007-01-25 2012-11-28 Roche Diagniostics GmbH Verwendung von IGFBP-7 bei der Beurteilung von Herzversagen
EP1970709B1 (de) * 2007-03-06 2013-07-10 Roche Diagnostics GmbH Verwendung von Peptiden vom Typ BNP zur Vorhersage des Dialysebedarfs
DE102007010834A1 (de) * 2007-03-03 2008-09-04 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten
DE102007022367A1 (de) * 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten
EP2210111A1 (de) * 2007-10-10 2010-07-28 Roche Diagnostics GmbH Natriuretisches peptid/troponin-verhältnis zur beurteilung bereits vorhandener myokard-fehlfunktion bei patienten mit akutem koronarsyndrom
WO2009047283A2 (en) 2007-10-10 2009-04-16 Roche Diagnostics Gmbh Means and methods for monitoring myocardial infarction and its treatment
CN102084251A (zh) * 2008-02-22 2011-06-01 奥塔哥创新有限公司 用于急性冠状动脉疾病的生物标志物
JP2011516038A (ja) 2008-03-12 2011-05-26 オタゴ イノベーション リミテッド バイオマーカー
DK2265641T3 (en) 2008-03-12 2018-04-23 Otago Innovation Ltd Biomarkers
ES2590213T3 (es) 2008-04-18 2016-11-18 Critical Care Diagnostics, Inc. Predicción del riesgo a sufrir episodios cardíacos adversos graves
WO2010007041A1 (en) * 2008-07-14 2010-01-21 Roche Diagnostics Gmbh Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure
CN102334031B (zh) * 2008-12-08 2014-10-08 美艾利尔圣地亚哥有限公司 组合的尿钠肽检测
CN102812359A (zh) * 2009-11-13 2012-12-05 Bg医药公司 心肌梗死的风险因子和预测
WO2011064358A1 (en) * 2009-11-27 2011-06-03 Roche Diagnostics Gmbh Method for diagnosing and monitoring cardiac ischemia in patients with acute chest pain and without myocardial infarction
US20110306148A1 (en) 2010-06-14 2011-12-15 Siemens Healthcare Diagnostics Inc. Composition for use as an assay reagent
EP2596010B1 (de) 2010-07-19 2017-04-12 Otago Innovation Limited Signalbiomarker
ES2750126T3 (es) 2011-03-17 2020-03-25 Critical Care Diagnostics Inc Procedimientos de predicción del riesgo de un resultado clínico adverso
RU2570755C2 (ru) * 2011-07-28 2015-12-10 Б.Р.А.Х.М.С. Гмбх СРЕДНЕ-РЕГИОНАЛЬНЫЙ ПРЕДШЕСТВЕННИК ПРЕДСЕРДНОГО НАТРИЙУРЕТИЧЕСКОГО ПЕПТИДА (pro-ANP) ДЛЯ ИДЕНТИФИКАЦИИ ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ, НАЧАВШЕЙСЯ МЕНЬШЕ ЧЕМ 48 ЧАСОВ ТОМУ НАЗАД
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
EP3088900B1 (de) 2011-10-17 2020-08-12 Roche Diagniostics GmbH Troponin als marker für intermittierendes vorhofflimmern
EP2594940A1 (de) * 2011-11-16 2013-05-22 Koninklijke Philips Electronics N.V. Partikelabstoßung zur Verbesserung des Oberflächenkontakts in Magnetpartikelimmuntests
WO2013079567A2 (en) * 2011-12-01 2013-06-06 Roche Diagnostics Gmbh Nt-proanp and nt-probnp for the diagnosis of stroke
WO2013141716A1 (en) 2012-03-20 2013-09-26 Christopher Joseph Pemberton Biomarkers
WO2014031764A1 (en) 2012-08-21 2014-02-27 Critical Care Diagnostics, Inc. Multimarker risk stratification
CN103304665A (zh) * 2013-05-21 2013-09-18 上海贝西生物科技有限公司 一种抗氨基末端脑利钠肽前体单克隆抗体及其应用
US20170049856A1 (en) * 2014-04-28 2017-02-23 Juventas Therapeutics, Inc. Sdf-1 delivery for treating advanced ischemic cardiomyopathy
CN105085659B (zh) * 2014-05-20 2021-02-19 深圳大学 一种重组利钠肽及其制备方法
CN111480076A (zh) * 2017-10-18 2020-07-31 艾德里诺医药公司 抗肾上腺髓质素（adm）结合剂治疗下的疗法监测
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR005600A0 (en) * 2000-09-12 2000-10-05 University Of Sydney, The Diagnostic assay
US6461828B1 (en) * 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
US7432107B2 (en) * 2005-01-24 2008-10-07 Roche Diagnostics Operations, Inc. Cardiac hormones for assessing cardiovascular risk
CA2598582A1 (en) * 2005-02-17 2006-08-24 Georg Hess Use of nt-proanp/nt-probnp ratio for diagnosing cardiac dysfunctions
ES2657087T3 (es) * 2005-07-29 2018-03-01 Koninklijke Philips N.V. Monitorización de péptidos natriuréticos cardiacos durante el diagnóstico, manejo y tratamiento de enfermedades cardiacas
CA2650201C (en) * 2006-04-24 2020-10-20 James V. Snider Predicting mortality and detecting severe disease
EP1882945A1 (de) * 2006-07-28 2008-01-30 F.Hoffmann-La Roche Ag Vorrichtungen und Verfahren zur Differentierung zwischen herz- und lungenbedingten Ursachen für akute Atemnot
DE602006010705D1 (de) * 2006-09-15 2010-01-07 Roche Diagnostics Gmbh Biochemische Marker für akute Lungenembolie
DE602006015964D1 (de) * 2006-09-20 2010-09-16 Roche Diagnostics Gmbh Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion
US9012151B2 (en) * 2006-11-09 2015-04-21 B.R.A.H.M.S. Gmbh Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin

Also Published As

Publication number Publication date
EP1889073A1 (de) 2008-02-20
EP1731910A1 (de) 2006-12-13
EP1889073B1 (de) 2010-05-26
US7608418B2 (en) 2009-10-27
WO2006131529A1 (en) 2006-12-14
JP4828600B2 (ja) 2011-11-30
ATE469353T1 (de) 2010-06-15
CN101194167A (zh) 2008-06-04
JP2008542778A (ja) 2008-11-27
US20090042228A1 (en) 2009-02-12
CA2607264A1 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
DE602006014535D1 (de) Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen
Zivkovic et al. A sustained reduction in serum cholinesterase enzyme activity predicts patient outcome following sepsis
Gempp et al. Reversible myocardial dysfunction and clinical outcome in scuba divers with immersion pulmonary edema
JP2007523324A5 (de)
ATE373827T1 (de) Kombination von markern für diabetes typ 1 und 2
Sheinerman et al. Early detection of neurodegenerative diseases: circulating brain-enriched microRNA
ATE537454T1 (de) Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15
RU2014145259A (ru) Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности
Cai et al. Predictive value of phosphorylated axonal neurofilament subunit H for clinical outcome in patients with acute intracerebral hemorrhage
ATE483982T1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
EP2227696A1 (de) Mittel und verfahren zur risikobewertung von patienten bei der einlieferung in die notfallstation auf gdf-15-basis
ES2628134T3 (es) Procedimiento para diagnosticar y monitorizar la isquemia cardíaca en pacientes con dolor torácico agudo y sin infarto de miocardio
JP2021156891A (ja) 軽度認知障害（ｍｃｉ）の診断、アルツハイマー病（ａｄ）型認知症の発症の予測、ならびにｍｃｉの処置または認知症発症の予防のための薬剤のスクリーニングおよびモニタリング
JP5715636B2 (ja) 循環系事象と虚血性事象を鑑別するためのＮＴ−ｐｒｏＡＮＰおよびＳＦｌｔ−１
DE602006015964D1 (de) Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion
CN103765219B (zh) 用于鉴定小于48小时之前发作的心房纤维性颤动患者的中段前心钠肽(pro‑ANP)
Meyer et al. Plasma mid-regional pro-adrenomedullin levels are inversely associated with anxiety but unrelated to depression: Results from the observational DIAST-CHF study in patients with cardiovascular risk factors
ATE477329T1 (de) Verfahren zur detektion der in-vivo-aktivität von neurotrypsin, verwendung des verfahrens und verwendung des c-terminal 22-kda-fragments als biomarker bei der diagnose und überwachung von störungen im zusammenhang mit neurotrypsin
ES2657087T3 (es) Monitorización de péptidos natriuréticos cardiacos durante el diagnóstico, manejo y tratamiento de enfermedades cardiacas
WO2008125681A8 (en) Means and methods for assessing the risk of a cardiac intervention in patients suffering from a stable coronary heart disease based on gdf-15
DE502004012230D1 (de) Verfahren zur diagnose von erkrankungen unter bestimmung von apolipoprotein c-i
ES2706539T3 (es) Método de diagnóstico in vitro de la Enfermedad de Alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo
Hirons et al. P215 RFC1 disorder; a genetic, neuropathic cause of chronic cough
WO2014108397A4 (en) A method for predicting the risk of getting cancer or diagnosing cancer in a subject
US20230176077A1 (en) Ret (rearranged during transfection) for the assessment of stroke

Legal Events

Date Code Title Description
8364 No opposition during term of opposition